Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

Pas encore traduit Pas encore traduit
Auteurs
Catégorie Primary study
Registry of Trialsclinicaltrials.gov
Year 2008

Cet article est inclus dans 1 Systematic review Systematic reviews (1 reference)

This article is part of the following publication threads:
This article is part of the following matrixes of evidence:
Loading references information
The primary objective of the trial is to demonstrate non-inferiority of 220 mg oral dabigatran etexilate compared to 40 mg subcutaneous enoxaparin administered once daily. Safety and efficacy will be compared between the treatment groups.
Epistemonikos ID: 5bd03734e15f7ee7eb4f237286a61a5ad6a6e1e3
First added on: Aug 22, 2016